CART22-65s

CART22-65s is an autologous chimeric antigen receptor (CAR) T-cell therapy developed by the University of Pennsylvania for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). The therapy consists of patient-derived T cells genetically modified via a lentiviral vector to express a chimeric antigen receptor targeting the CD22 antigen, which is commonly expressed on B-cell malignancies. It utilizes an anti-CD22 single-chain variable fragment (scFv) linked to TCRζ and 4-1BB costimulatory domains. CART22-65s is primarily investigated for patients who have relapsed after CD19-targeted CAR T-cell therapy, often administered alone or in combination with humanized anti-CD19 CAR T cells (huCART19) to mitigate antigen escape and prevent disease recurrence.

Other names

anti-CD22 CAR T cellsanti-CD-22 CAR T cellsanti-CD 22 CAR T cellsCART22CART-22CART 22